Clinical Scorecard: Assessment of tirofiban's effectiveness and safety in acute ischemic stroke cases without large or medium vessel occlusion: a systematic review and meta-analysis

At a Glance

Key Highlights

• Tirofiban significantly improves 90-day functional outcomes in non-LVO/MVO AIS patients.
• Higher likelihood of achieving excellent (mRS 0-1) and favorable (mRS 0-2) functional outcomes with tirofiban.
• No significant increase in the risk of symptomatic intracerebral hemorrhage or 90-day mortality.
• Increased risk of peripheral bleeding associated with tirofiban use.
• Functional benefits primarily observed in patients without prior IVT.

Guideline-Based Recommendations

Diagnosis

• Assess for acute ischemic stroke using clinical criteria and imaging.

Management

• Consider tirofiban for patients with non-LVO/MVO AIS, especially those not receiving IVT.

Monitoring & Follow-up

• Monitor for peripheral bleeding and other adverse effects during tirofiban therapy.

Risks

• Evaluate the risk of peripheral bleeding when administering tirofiban.

Patient & Prescribing Data

Patients with non-LVO/MVO acute ischemic stroke.

Tirofiban may enhance functional recovery, particularly in patients not treated with IVT.

Clinical Best Practices

• Utilize tirofiban in conjunction with standard care for acute ischemic stroke.
• Carefully assess bleeding risks before initiating tirofiban therapy.
• Conduct regular follow-ups to evaluate functional outcomes and safety.

References

• Systematic Review and Meta-Analysis